SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 100 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,374,201 | +47.9% | 65,657 | +49.3% | 0.04% | +38.5% |
| Q1 2023 | $928,836 | +246.2% | 43,979 | +317.1% | 0.03% | +225.0% |
| Q4 2022 | $268,319 | -19.7% | 10,543 | -29.7% | 0.01% | -77.1% |
| Q4 2020 | $334,000 | -20.1% | 14,997 | -47.0% | 0.04% | +29.6% |
| Q3 2020 | $418,000 | +62.0% | 28,309 | +62.4% | 0.03% | +50.0% |
| Q2 2020 | $258,000 | -26.9% | 17,435 | -56.7% | 0.02% | -53.8% |
| Q4 2017 | $353,000 | +165.4% | 40,274 | +254.8% | 0.04% | +14.7% |
| Q3 2017 | $133,000 | -53.0% | 11,351 | -44.9% | 0.03% | -5.6% |
| Q1 2017 | $283,000 | – | 20,595 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |